{
    "nct_id": "NCT03926117",
    "official_title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition",
    "inclusion_criteria": "* 18 years of age\n* Stage 3-5 CKD\n* hs-CRP > 2.0 mg/L\n* Comply with contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Low neutrophil count\n* Low platelet count\n* Spot urine protein to creatinine ration > 4000 mg/g\n* ALT/AST >2.5x ULN\n* TSAT < 10%\n* Positive TB test\n* Evidence of HIV, hepatitis B\n* Blind or illiterate\n* Expected to require blood transfusion\n* Thromboembolic event within 12-weeks\n* Evidence of active infection\n* Peptic ulcer disease, diverticulitis, inflammatory bowel disease\n* Uncontrolled hypertension\n* Planned coronary revascularization\n* Major cardiac surgery, CHF\n* Active malignancy, bone marrow or organ transplant\n* Allergy to study drug\n* Treatment with investigational drug, treatment with HIF stabilizer or ESA\n* Use of immunosuppressive drugs, systemic antibiotics\n* Breastfeeding, any other significant medical history",
    "miscellaneous_criteria": ""
}